Comparing transdermal HRT therapies
when starting patients on HRT
|
Lenzetto® (spray) 
|
Gel
|
Patch
|
|---|---|---|
| Avoids first-pass liver metabolism | ||
| Yes1 | Yes1 | Yes1 |
| Dosing and administration | ||
| 1, 2 or 3 metered-dose sprays of Lenzetto® (each containing 1.53 mg of estradiol) applied to inner forearm daily2 |
Oestrogel® 750 μg estradiol/actuation gel: Pump-pack actuation. Two pumps (2.5g) of Oestrogel® once daily (1.5 mg estradiol) is the usual starting dose3 Sandrena® 1mg estradiol gel: Gel sachet. The usual starting dose is 1.0 mg estradiol (1.0 g gel) daily but the selection of the initial dose can be based on the severity of the patient’s symptoms. Dose can be readjusted after 2-3 cycles individually from 0.5 g to 1.5 g per day4 |
Evorel Sequi® 50 mcg estradiol/ day patch: adhesive patch delivering 25, 50, 75 and 100 mcg of estradiol over 24 hours5 |
| Drug half-life | ||
| Estradiol values did not return to baseline by 168 hours after the last dose7 |
Oestrogel® 750 μg estradiol/actuation gel: 36 hours8 Sandrena® 1 mg estradiol gel: half-life not available9 |
Evorel Sequi® 50 mcg estradiol/day patch: 6.6 hours5 |
| Application site adverse events | ||
|
Skin irritation for Lenzetto®:
uncommon (≥1/1,000 to
<1/100).2 Treatment-related application site reaction rate was similar to placebo10 |
Skin reactions for Oestrogel® and Sandrena®: range from common (≥1/100 to <1/10) to uncommon (≥1/1,000 to <1/100)3,4 | Evorel Sequi® local skin reactions (including pruritis and rash): common5 |